TEL AVIV, Israel, August 28, 2018 /PRNewswire/ —
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, Board of Directors is proud to announce its addition of Dr Giloz-Ran, former manager of Grants Capital Investment, at INTEL Corporation, Israel – to its advisory board.
“We are honored to have Dr. Giloz-Ran join our Board of Advisors, her exceptional record in international business management suits us well as our state-of-the-art laboratory comes into operation and we are being approached by potential medical partners to explore joint ventures,” said Eyal Ballan, CTO.
Estery Giloz-Ran is a PhD and CPA who has over a decade specializing in multi-national business development. Dr Gilon-Raz served as head of grants capital investment law, at INTEL Corporation, Israel. She is past Chairman of the Board of Tamir Fishman, a venture capital firm; has been external director in eight significant public companies such as KAMADA (NASDAQ: KMDA); Director at Emerald, a medical device company; lecturer at Bar Ilan University, Ben Gurion University; and visiting professor at the Stern Business School (New York).
“I’m excited to join CNBX’s outstanding vision,” says Dr Gilon-Raz. “The need for a natural cancer cure is a well-known fact and I’m happy to help the company reaching that goal, using new collaborations with leading global players.”
Dr. Giloz-Ran received her CPA as a certified public accountant in 2007; MBA (cum laude) from Ben Gurion University in 2010, PhD in accounting and finance from Ben Gurion University (2013), and did her postdoctoral work at New York University in 2014.
Dr. Giloz-Ran joins the current Board of Advisors which includes Dr. Gil Feiler, Business Development, Scientific Advisor; Prof. Amos Toren, MD, Medical Advisor; Dr. Tal Mofkadi, financial advisor, and Dr. Sigalit Ariely– Portnoy, Strategic Regulatory Advisor, Clinical, Quality and Validation.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a United States public company that is developing a platform that leverages drug screening and artificial intelligence to develop cannabinoid-based therapies for palliative care and cancer treatments that are more precise to a patient’s profile and specific cancer. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move medical cannabinoids into the future of cancer therapies. The company’s R&D is based in Israel, where it is licensed by the Health Ministry to conduct scientific and clinical research on cannabinoid formulations.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, Cannabics Pharmaceuticals’ latest 10-Q Report filed on July 16th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself, and bear our name as its Source.